Prolonged Survival With Adjuvant Ipilimumab in Stage 3 Melanoma Prolonged Survival With Adjuvant Ipilimumab in Stage 3 Melanoma

New results show that adjuvant ipilimumab improves survival, but the drug was used at a higher dose of 10 mg/kg and had serious side effects.Medscape Medical News
Source: Medscape Dermatology Headlines - Category: Dermatology Tags: Hematology-Oncology News Source Type: news
More News: Dermatology